GlassScriptPhysician profile
Ira C Robinson
NPI 1174615116
$12,497.31
in general payments reported to CMS, 2019-2025
58 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,800 · 2020: $1,521 · 2021: $1,864 · 2022: $1,729 · 2023: $2,012 · 2024: $1,797 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,469 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,468.60 |
| Education | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,384.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,360.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,184.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $863.27 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $832.85 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Amarin Pharma, INC. | $776.65 | 2019-2022 | |
| Abbvie INC. | $746.17 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $469.46 | 2021-2025 | |
| Astellas Pharma US INC | $420.67 | 2019-2025 | Veozah |
| Amgen INC. | $355.51 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $293.94 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Daiichi Sankyo INC. | $293.27 | 2019-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.38 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $212.34 | 2020-2024 | Gvoke Hypopen |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $195.17 | 2020-2025 | Freestyle Libre 3, Octrode |
| Insulet Corporation | $174.29 | 2019-2024 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $156.01 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $152.08 | 2022-2024 | Quviviq |
| Ironwood Pharmaceuticals, INC | $151.42 | 2019-2024 | Linzess |
| Otsuka America Pharmaceutical, INC. | $147.06 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $142.80 | 2019-2025 | |
| Corcept Therapeutics | $124.58 | 2020-2025 | Korlym |
| Exact Sciences Corporation | $112.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $111.70 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $111.28 | 2023 | Hetlioz, Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $95.62 | 2022 | |
| Currax Pharmaceuticals LLC | $94.53 | 2021-2024 | Nexletol, Contrave, Nexlizet |
| Teva Pharmaceuticals USA, INC. | $93.57 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $89.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.02 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $67.14 | 2019-2020 | |
| Dexcom, INC. | $60.60 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.09 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $49.06 | 2025 | Gemtesa |
| Allergan, INC. | $47.46 | 2019-2020 | |
| Horizon Therapeutics Plc | $47.05 | 2019-2020 | |
| Eisai INC. | $46.24 | 2021 | |
| Merck Sharp & Dohme LLC | $42.07 | 2019-2023 | Belsomra |
| Lundbeck LLC | $33.10 | 2024 | Rexulti, Brintellix |
| Mylan Specialty L.P. | $32.47 | 2022-2023 | Yupelri |
| Atland Pharmaceuticals, LLC | $31.68 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Cequr Corporation | $24.67 | 2023 | Cequr Simplicity |
| Actelion Pharmaceuticals US, INC. | $23.84 | 2025 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $23.53 | 2025 | Symbravo |
| Paratek Pharmaceuticals, INC. | $22.14 | 2024 | Nuzyra |
| Gilead Sciences, INC. | $19.63 | 2025 | |
| Kaleo, INC. | $19.02 | 2020 | |
| Almatica Pharma LLC | $18.60 | 2021 | |
| Athena Bioscience, LLC | $18.03 | 2023 | Qdolo |
| Clarus Therapeutics INC. | $14.65 | 2021 | |
| Valinor Pharma, LLC | $14.60 | 2025 | Movantik |
| Sanofi Pasteur INC. | $14.50 | 2019 | |
| Senseonics, Incorporated | $14.00 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.61 | 2020 | |
| Genentech USA, INC. | $13.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.34 | 2022 | |
| Impel Pharmaceuticals INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.